Praluent (alirocumab) is an antibody pharmaceutical. Alirocumab was first approved as Praluent on 2015-07-24. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
|Indication||atherosclerosis, dyslipidemias, hypercholesterolemia|
|Drug Class||Monoclonal antibodies: fully human, cardiovascular indications|